Skip to content

Madrigal Pharmaceuticals, Inc.

MDGL· NasdaqCore metricsCIK 1157601

Pharmaceutical preparations552 peers

Last sale
Nov 12, 2026 · -1.71%
Market cap
$9.87B
23.23M shares
Filings
1,024
$431.27M
Q3 2026+432.1% FY25 yoy
$55.44M
Q3 2026N/M FY25 yoy
$55.99M
Q3 2026N/M FY25 yoy
-$35.58M
Q3 2026derivedN/M FY25 yoy
$1.83
Q3 2026N/M FY25 yoy
$514.64M
Q3 2026+98.7% FY25 yoy
$9.87B
—
6.9×
15.7×
-1.71%
—

Twelve months to Sep 30, 2026 · derived

Price

$425.0721.50%$116.44past year
Nov 12, 2026 · IEX last sale
Figure
Range
IEX last saleClose of recordAs traded

Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Financials

Revenue

$958.40MFY 2025
$958.40M0FY 2012FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
PeriodEndedValueKindSource trail
FY 20252025-12-31$958,403,000reported
FY 20242024-12-31$180,133,000reported
FY 20232023-12-31$0reported
FY 20222022-12-31$0reported
FY 20212021-12-31$0reported
FY 20202020-12-31$0reported
FY 20192019-12-31$0reported
FY 20182018-12-31$0reported
FY 20172017-12-31$0reported
FY 20122012-12-31$147,000reported

Capital returns

Fiscal yearDividendsBuybacksTotalPer shareSharesShares · yoyof free cash flow
FY2012—$32.00K$32.00K—69.05M sh+19.8%—

Pharmaceutical preparations

Madrigal Pharmaceuticals, Inc. is the 36th largest of the 553 covered companies the SEC files under this code, by revenue. SIC 2834

Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.

Madrigal Pharmaceuticals, Inc. · CIK 1157601 · Engraved from SEC EDGAR